← Back to Clinical Trials
Recruiting NCT06924463

NCT06924463 Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06924463
Status Recruiting
Phase
Sponsor Lille University
Condition Rhabdomyosarcoma
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2025-03-13
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 0 Years
Max Age 25 Years
Study Type OBSERVATIONAL
Interventions
None AHT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2025-03-13 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.

Eligibility Criteria

Inclusion Criteria: * Age between 0 and 25 years at the time of initial diagnosis * Diagnosis of rhabdomyosarcoma confirmed histologically * Care at the Oscar Lambret Center between January 2005 and November 2024 * No objection to the re-use of data and biological samples collected as part of care for research activities. Exclusion Criteria: * Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret; * Patient under guardianship or trusteeship.

Frequently Asked Questions

Who can join the NCT06924463 clinical trial?

This trial is open to participants of all sexes, aged 0 Years or older, up to 25 Years, studying Rhabdomyosarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06924463 currently recruiting?

Yes, NCT06924463 is actively recruiting participants. Visit ClinicalTrials.gov or contact Lille University to inquire about joining.

Where is the NCT06924463 trial being conducted?

This trial is being conducted at Lille, France.

Who is sponsoring the NCT06924463 clinical trial?

NCT06924463 is sponsored by Lille University. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology